Importer of Controlled Substances Application: Scientific Botanical Pharmaceutical, Inc., 29742-29743 [2020-10625]

Download as PDF 29742 Federal Register / Vol. 85, No. 96 / Monday, May 18, 2020 / Notices Controlled substance Drug code Tetrahydrocannabinols ..................................................................................................................................................... Codeine-N-oxide ............................................................................................................................................................... Dihydromorphine .............................................................................................................................................................. Difenoxin ........................................................................................................................................................................... Morphine-N-oxide ............................................................................................................................................................. Normorphine ..................................................................................................................................................................... Norlevorphanol ................................................................................................................................................................. Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ................................................................................ Butyryl Fentanyl ................................................................................................................................................................ Fentanyl related-substances as defined in 21 CFR 1308.11(h) ...................................................................................... Amphetamine ................................................................................................................................................................... Methamphetamine ............................................................................................................................................................ Lisdexamfetamine ............................................................................................................................................................ Methylphenidate ............................................................................................................................................................... Nabilone ........................................................................................................................................................................... 4-Anilino-N-phenethyl-4-piperidine (ANPP) ...................................................................................................................... Codeine ............................................................................................................................................................................ Dihydrocodeine ................................................................................................................................................................. Oxycodone ....................................................................................................................................................................... Hydromorphone ................................................................................................................................................................ Diphenoxylate ................................................................................................................................................................... Ecgonine ........................................................................................................................................................................... Hydrocodone .................................................................................................................................................................... Levorphanol ...................................................................................................................................................................... Meperidine ........................................................................................................................................................................ Methadone ........................................................................................................................................................................ Methadone intermediate ................................................................................................................................................... Dextropropoxyphene, bulk (non-dosage forms) ............................................................................................................... Morphine ........................................................................................................................................................................... Oripavine .......................................................................................................................................................................... Thebaine ........................................................................................................................................................................... Opium tincture .................................................................................................................................................................. Opium, powdered ............................................................................................................................................................. Oxymorphone ................................................................................................................................................................... Noroxymorphone .............................................................................................................................................................. Alfentanil ........................................................................................................................................................................... Remifentanil ...................................................................................................................................................................... Sufentanil .......................................................................................................................................................................... Tapentadol ........................................................................................................................................................................ Fentanyl ............................................................................................................................................................................ The company plans to manufacture bulk active pharmaceutical ingredients (APIs) for distribution to its customers. In reference to drug code 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture this drug as synthetic. No other activities for this drug code is authorized for this registration. William T. McDermott, Assistant Administrator. Drug Enforcement Administration [Docket No. DEA–646] Importer of Controlled Substances Application: Scientific Botanical Pharmaceutical, Inc. ACTION: Notice of application. Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before June 17, 2020. Such persons may also file a written request for a hearing on the application on or before June 17, 2020 ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 DATES: [FR Doc. 2020–10601 Filed 5–15–20; 8:45 am] BILLING CODE 4410–09–P jbell on DSKJLSW7X2PROD with NOTICES DEPARTMENT OF JUSTICE Jkt 250001 PO 00000 Frm 00064 Fmt 4703 In accordance with 21 CFR 1301.34(a), this is notice that on January 27, 2017, Scientific Botanical Pharmaceutical, Inc., 1225 West Deer Valley Road Phoenix, Arizona 85027, applied to be registered as an importer of the following basic class(es) of controlled substances: Drug Code Sfmt 4703 I I I I I I I I I I II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II SUPPLEMENTARY INFORMATION: Marihuana ................................................................................................................................................................ 18:03 May 15, 2020 7370 9053 9145 9168 9307 9313 9634 9821 9822 9850 1100 1105 1205 1724 7379 8333 9050 9120 9143 9150 9170 9180 9193 9220 9230 9250 9254 9273 9300 9330 9333 9630 9639 9652 9668 9737 9739 9740 9780 9801 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. Controlled substance VerDate Sep<11>2014 Schedule E:\FR\FM\18MYN1.SGM 18MYN1 7360 Schedule I 29743 Federal Register / Vol. 85, No. 96 / Monday, May 18, 2020 / Notices Controlled substance Drug Code Tetrahydrocannabinols ............................................................................................................................................ The company plans to import the listed controlled substances as seeds, cuttings, or other plant tissue material in order to conduct research on genetic development and manufacturing processes. This notice does not constitute an evaluation or determination of the merits of the company’s application. William T. McDermott, Assistant Administrator. [FR Doc. 2020–10625 Filed 5–15–20; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE [OMB Number 1117–0006] Agency Information Collection Activities; Proposed eCollection, eComments Requested; Revision of a Previously Approved Collection; The National Forensic Laboratory Information System Collection of Analysis Data Drug Enforcement Administration, Department of Justice. ACTION: 60-Day Notice. AGENCY: The Department of Justice (DOJ), Drug Enforcement Administration (DEA), will be submitting the following information collection request to the Office of Management and Budget for review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: Comments are encouraged and will be accepted for 60 days until July 17, 2020. FOR FURTHER INFORMATION CONTACT: If you have comments, especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Scott A. Brinks, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (571) 362–3261. SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary jbell on DSKJLSW7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:03 May 15, 2020 Jkt 250001 for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information proposed to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other forms of information technology, e.g., permitting electronic submission of responses. Overview of This Information Collection 1. Type of Information Collection: Revision of a currently approved collection. 2. Title of the Form/Collection: The National Forensic Laboratory Information System Collection of Analysis Data. 3. The agency form number, if any, and the applicable component of the Department sponsoring the collection: There are no form numbers for the collection. The applicable component within the Department of Justice is the Drug Enforcement Administration, Diversion Control Division. 4. Affected public who will be asked or required to respond, as well as a brief abstract: Affected public (Primary): Forensic Science Laboratory Management. Affected public (Other): None. Abstract: This collection provides the Drug Enforcement Administration (DEA) with a national database on analyzed drug evidence from nonfederal laboratories. Information from this database is combined with the other existing databases to develop more accurate, up-to-date information on abused drugs. This database represents a voluntary, cooperative effort on the part of participating laboratories to provide a centralized source of analyzed drug data. 5. An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: The DEA estimates that 2,640 persons annually for this collection at PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 Schedule 7370 I 2.2 hour per respondent, for an annual burden of 5,812 hours. 6. An estimate of the total public burden (in hours) associated with the proposed collection: The DEA estimates this collection takes 5,812 annual burden hours. If additional information is required, please contact: Melody Braswell, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE, Suite 3E.405B, Washington, DC 20530. Dated: May 12, 2020. Melody Braswell, Department Clearance Officer for PRA, U.S. Department of Justice. [FR Doc. 2020–10545 Filed 5–15–20; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE [OMB 1121–NEW] Agency Information Collection Activities; Proposed Collection Comments Requested; New Data Collection: Office for Victims of Crime (OVC) Tribal Financial Management Center (TFMC) Needs Assessment and Evaluation OMB Package Office for Victims of Crime, Department of Justice. ACTION: 60-day notice. AGENCY: The Department of Justice, Office of Justice Programs, Office for Victims of Crime will submit the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. DATES: The purpose of this notice is to allow for an additional 60 days for public comment until July 17, 2020. FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact please contact James Simonson, Associate Director, (202) 353–9313, Office for Victims of Crime, Office of SUMMARY: E:\FR\FM\18MYN1.SGM 18MYN1

Agencies

[Federal Register Volume 85, Number 96 (Monday, May 18, 2020)]
[Notices]
[Pages 29742-29743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-10625]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-646]


Importer of Controlled Substances Application: Scientific 
Botanical Pharmaceutical, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before June 17, 2020. 
Such persons may also file a written request for a hearing on the 
application on or before June 17, 2020

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on January 27, 2017, Scientific Botanical 
Pharmaceutical, Inc., 1225 West Deer Valley Road Phoenix, Arizona 
85027, applied to be registered as an importer of the following basic 
class(es) of controlled substances:

------------------------------------------------------------------------
          Controlled substance               Drug Code       Schedule
------------------------------------------------------------------------
Marihuana...............................            7360               I

[[Page 29743]]

 
Tetrahydrocannabinols...................            7370               I
------------------------------------------------------------------------

    The company plans to import the listed controlled substances as 
seeds, cuttings, or other plant tissue material in order to conduct 
research on genetic development and manufacturing processes. This 
notice does not constitute an evaluation or determination of the merits 
of the company's application.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-10625 Filed 5-15-20; 8:45 am]
BILLING CODE 4410-09-P